1.

Timeline of OxCGRT’s Stringency Index and SARS-CoV-2 infection incidence* in the Netherlands during our study period with four predefined and separately studied periods colour-indi...

2.

Timeline of OxCGRT’s Stringency Index and SARS-CoV-2 infection incidence* in the Netherlands during our study period with four predefined and separately studied periods colour-indi...

3.

Timeline of OxCGRT’s Stringency Index and SARS-CoV-2 infection incidence* in the Netherlands during our study period with four predefined and separately studied periods colour-indi...

4.

Timeline of OxCGRT’s Stringency Index and SARS-CoV-2 infection incidence* in the Netherlands during our study period with four predefined and separately studied periods colour-indi...

5.

Timeline of OxCGRT’s Stringency Index and SARS-CoV-2 infection incidence* in the Netherlands during our study period with four predefined and separately studied periods colour-indi...

6.

Timeline of OxCGRT’s Stringency Index and SARS-CoV-2 infection incidence* in the Netherlands during our study period with four predefined and separately studied periods colour-indi...

7.

Timeline of OxCGRT’s Stringency Index and SARS-CoV-2 infection incidence* in the Netherlands during our study period with four predefined and separately studied periods colour-indi...

1.

Characteristics of all PICO and VASCO participants included in this study a .

2.

Characteristics of all PICO and VASCO participants included in this study a .

3.

Characteristics of all PICO and VASCO participants included in this study a .

1.

Fig 3 -

2.

Fig 3 -

3.

Fig 3 -

4.

Fig 3 -

5.

Fig 3 -

6.

Fig 3 -

7.

Fig 3 -

1.

Fig 4 -

2.

Fig 4 -

3.

Fig 4 -

1.

Fig 5 -

2.

Fig 5 -

3.

Fig 5 -

1.

Daily new confirmed COVID-19 cases per million people in Belgium and France.

2.

Daily new confirmed COVID-19 cases per million people in Belgium and France.

3.

Daily new confirmed COVID-19 cases per million people in Belgium and France.

4.

Daily new confirmed COVID-19 cases per million people in Belgium and France.

5.

Daily new confirmed COVID-19 cases per million people in Belgium and France.

6.

Daily new confirmed COVID-19 cases per million people in Belgium and France.

7.

Daily new confirmed COVID-19 cases per million people in Belgium and France.

1.

Daily new confirmed COVID-19 deaths per million people in Belgium and France.

2.

Daily new confirmed COVID-19 deaths per million people in Belgium and France.

3.

Daily new confirmed COVID-19 deaths per million people in Belgium and France.

4.

Daily new confirmed COVID-19 deaths per million people in Belgium and France.

5.

Daily new confirmed COVID-19 deaths per million people in Belgium and France.

6.

Daily new confirmed COVID-19 deaths per million people in Belgium and France.

7.

Daily new confirmed COVID-19 deaths per million people in Belgium and France.

1.

COVID-19 government response stringency on lockdown in Belgium and France.

2.

COVID-19 government response stringency on lockdown in Belgium and France.

3.

COVID-19 government response stringency on lockdown in Belgium and France.

4.

COVID-19 government response stringency on lockdown in Belgium and France.

5.

COVID-19 government response stringency on lockdown in Belgium and France.

6.

COVID-19 government response stringency on lockdown in Belgium and France.

7.

COVID-19 government response stringency on lockdown in Belgium and France.

1.

How the Macroeconomic Environment and Investment Climate Have Affected the Manufacturing Sector

2.

How the Macroeconomic Environment and Investment Climate Have Affected the Manufacturing Sector

3.

How the Macroeconomic Environment and Investment Climate Have Affected the Manufacturing Sector

1.

CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections

2.

CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections

3.

CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections

4.

CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections

5.

CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections

6.

CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections

7.

CXCR6-Mediated Simian Immunodeficiency Virus SIVagmSab Entry into Sabaeus African Green Monkey Lymphocytes Implicates Widespread Use of Non-CCR5 Pathways in Natural Host Infections